Prostate cancer has long been medicine's most frustrating puzzle when it comes to immunotherapy.
Over the past decade, immune checkpoint inhibitors have transformed the treatment of melanoma, lung cancer, and bladder cancer — turning once-terminal diagnoses into manageable conditions for many patients. But prostate cancer remained stubbornly unresponsive. It was described as **'immune-cold'**: a tumour that actively suppresses the immune response and hides from the body's own defences. Drug after drug failed.
That may be about to change.
**The Trial**
At the **2026 ASCO Genitourinary Cancers Symposium** in February, researchers from Vir Biotechnology presented Phase 1 data for **VIR-5500** — a novel immunotherapy drug designed specifically to crack the immune-cold problem in prostate cancer.
The trial enrolled 58 men with **metastatic castration-resistant prostate cancer (mCRPC)** — one of the most advanced and difficult-to-treat forms of the disease, affecting men whose cancer has spread and stopped responding to hormone therapy. These are patients who have run out of standard options.
**The Results**
At the highest dose cohorts tested (≥3,000 µg/kg), the results were described by independent oncologists as *'stunning'* and *'unprecedented'*:
📊 **82% of evaluable patients** (14 out of 17) experienced at least a **50% decline in PSA** — prostate-specific antigen, the primary blood marker for prostate cancer activity
📊 **53%** (9 out of 17) saw a **90% PSA drop**
📊 **29%** (5 out of 17) achieved a remarkable **99% reduction** in PSA
📊 Of the 11 patients in the highest-dose group with measurable tumours, **45% showed direct tumour shrinkage**
The safety profile was equally encouraging: 88% of all patients experienced only very mild side effects. No dose-limiting toxicities were observed. Cytokine release syndrome — a feared complication of some immunotherapy approaches — was limited to Grade 1 in almost all cases.
**One Man's Story**
Among the clinical details shared was the case of a 63-year-old man who had presented with **14 separate cancerous lesions in his liver** — an advanced metastatic picture with a grim prognosis.
After six cycles of VIR-5500, **all 14 liver lesions had completely resolved**.
A complete response in that context is not common in any cancer trial. In a cancer historically considered immune-unresponsive, it borders on the remarkable.
**How VIR-5500 Works**
VIR-5500 belongs to a class of drugs called **T-cell engagers** — molecules designed to bridge the gap between the immune system's killer T cells and tumour cells. Standard T-cell engagers have historically caused severe side effects because they activate T cells throughout the body, not just in tumours.
VIR-5500 solves this with a **'dual-masked' design**. The drug targets **PSMA (prostate-specific membrane antigen)** — a protein highly expressed on prostate cancer cells — but its T-cell activating function is chemically masked. It only unmasks and becomes active within the **tumour microenvironment** itself. Elsewhere in the body, it remains largely inert.
This is how the drug achieves strong anti-tumour effects while keeping side effects manageable — an elegant solution to a problem that has stalled other T-cell engager programmes.
**What Comes Next**
Vir Biotechnology is now advancing expanded dose cohorts. A registrational trial — the kind needed for regulatory approval — is planned for 2027. In February 2026, Astellas Pharma announced a global strategic collaboration with Vir to co-develop and commercialise VIR-5500, providing significant additional resources for the programme.
For the approximately **350,000 men who die of prostate cancer globally each year**, a genuinely effective immunotherapy would be transformative. The cancer that was long considered immune-cold may finally be warming to treatment.
*'These results are unprecedented for prostate cancer,'* one oncologist noted.
They are also, for many patients and families, the kind of results that restore hope. 💙🎗️
*Sources: ASCO Genitourinary Cancers Symposium, February 2026 · The Guardian (February 28, 2026) · Vir Biotechnology / Astellas Pharma*